Innoviva, INC

Innoviva, Inc. announced robust second quarter 2026 financial results, featuring significant year-over-year revenue growth and the launch of a new strategic healthcare asset.

Innoviva announces the resignations of two directors, Derek Small and Mark DiPaolo, and the subsequent appointment of Josephine Linden to its Board.

Innoviva, Inc. announced robust first-quarter 2026 financial results, showcasing significant year-over-year growth in net product sales and substantial value creation from its strategic healthcare asset portfolio.

Innoviva, Inc. held its Annual Meeting of Stockholders on May 4, 2026, where directors were elected, executive compensation was approved on an advisory basis, and Deloitte & Touche LLP was ratified as the independent auditor.

Innoviva, Inc. announced robust financial results for Q4 and full year 2025, driven by significant revenue growth, strong product sales, and the FDA approval of NUZOLVENCE.

Innoviva, Inc. announced robust third-quarter 2025 financial results, driven by strong product sales and royalty growth, alongside a new $125 million share repurchase program.

Innoviva, Inc. announced Q1 2026 results with total revenue of $98.0 million, a 11% increase year-over-year, driven by growth in net product sales and significant gains from strategic investments.

Innoviva reports a substantial increase in net income and product sales for Q3 2025, driven by commercialization efforts and strategic investments, alongside a new share repurchase program.

Innoviva, Inc. reported a significant turnaround in net income for Q2 2025, driven by robust growth in net product sales and favorable changes in investment fair values, alongside key pipeline advancements.

Innoviva's Q1 2025 saw stable royalty revenue, a significant increase in product sales, but a net loss due to unfavorable changes in the fair value of equity and long-term investments.

Innoviva's Q3 2024 results show revenue growth driven by increased product sales and royalties from partnered respiratory assets.

Innoviva's second quarter results show a mix of increased product sales and royalty revenue alongside significant investment losses.

Innoviva, Inc. filed an amended annual report to include the audited financial statements of its subsidiary, Armata Pharmaceuticals, Inc., which reported substantial losses and a going concern doubt.

Innoviva reports significant revenue growth in 2025 driven by strong product sales and strategic investments, despite a slight dip in royalty revenue.

Innoviva, Inc. files an amendment to its 2024 annual report to include the audited consolidated financial statements of Armata Pharmaceuticals, Inc.

Innoviva's 2024 results show increased product sales offset by equity investment losses, while the company advances its pipeline with a planned NDA submission for Zoliflodacin.

Innoviva Inc. has filed an amendment to its annual report to include the audited financial statements of Armata Pharmaceuticals, Inc., a company in which it holds a significant stake.

Innoviva files an amendment to its 2023 annual report to correct a clerical error in the audit report, while also providing detailed financial results for the year.

Innoviva, Inc. CFO Stephen Basso acquired shares via an employee plan and disposed of shares to cover tax obligations.

Innoviva, Inc. CEO Pavel Raifeld acquired shares via an employee stock purchase plan and disposed of shares to cover tax obligations.

Innoviva Chief Accounting Officer Marianne Zhen reported the withholding of 1,127 shares to cover tax obligations related to equity vesting.

Innoviva, Inc. reports the grant of restricted stock units and stock options to Director Josephine Linden upon her board appointment.

Innoviva Inc. Chief Accounting Officer Marianne Zhen acquired 12,766 shares of common stock and was granted stock options.

Innoviva, Inc. reports that Director Sarah J. Schlesinger was granted stock options and restricted stock units following the 2026 annual meeting.

Innoviva, Inc. announces its 2026 Annual Meeting of Stockholders to vote on director elections, executive compensation, auditor ratification, and a new 2026 Equity Incentive Plan, following a strong 2025 financial performance.

Innoviva, Inc. will hold its annual meeting of stockholders on May 19, 2025, to elect directors, approve executive compensation, and ratify the appointment of Deloitte & Touche LLP as the independent auditor.

Innoviva, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 19, 2025, featuring proposals for director elections, executive compensation approval, and auditor ratification.

Innoviva, Inc. will hold its annual meeting of stockholders on June 17, 2024, to elect directors, approve executive compensation, and ratify the appointment of Deloitte & Touche LLP as the independent auditor.

Innoviva, Inc. will hold its 2024 Annual Meeting of Stockholders on June 17, 2024, to elect directors, approve executive compensation, and ratify the selection of independent auditors.

Innoviva, Inc. has expanded its financial commitment to Armata Pharmaceuticals through a new $25 million secured credit agreement.

Armata Pharmaceuticals, Inc. and Innoviva, Inc. have extended maturity dates for several credit agreements and expiration dates for warrants and a voting agreement, solidifying their financial relationship.

Innoviva, Inc. and its subsidiary have increased their beneficial ownership in Armata Pharmaceuticals to 83.3% and provided a new $15 million secured loan.

Sarissa Capital Management LP and Alexander J. Denner have significantly reduced their beneficial ownership in Innoviva, Inc. to below 5%, ceasing to be subject to certain SEC reporting requirements.

Innoviva, Inc. and its subsidiary have provided Armata Pharmaceuticals with a new $10 million secured loan and extended the maturity dates of three existing credit agreements to March 2026, solidifying their beneficial ownership to 85.2%.

Sarissa Capital Management LP and its Chief Investment Officer, Alexander J. Denner, have significantly reduced their beneficial ownership in Innoviva, Inc., disposing of over 2 million shares in early March 2025, bringing their stake down to 8.4%.

Vanguard Capital Management has reported a 5.01% ownership stake in Innoviva Inc., holding 3,704,185 shares.

Vanguard Portfolio Management has reported beneficial ownership of 5.79% of Innoviva Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Innoviva Inc. following an internal realignment, disaggregating its reporting.

Renaissance Technologies LLC and its parent company have disclosed a 5.63% beneficial ownership stake in Innoviva, Inc. as of December 31, 2025.

Dimensional Fund Advisors LP has filed an amended Schedule 13G, reporting a 5.8% beneficial ownership stake in Innoviva Inc. as of December 31, 2025.

Bank of Nova Scotia reported a beneficial ownership of 3.37% in Innoviva, Inc., holding 2,179,005 shares of common stock as of September 30, 2025.